IIJIMA Hiroaki
- 助教
- 学位:学士(医学)
基本情報
所属
- Undergraduate School of Medicine / Faculty of Medicine
詳細情報
研究キーワード
- Infection
- Molecular biology
- Otorhinolaryngology
- Head and neck cancer
研究分野
- Life sciences Molecular biology
- Life sciences Tumor diagnostics and therapeutics
- Life sciences Otorhinolaryngology
受賞
- Tokai Medical Association Tokai Journal Best Paper Award A Study of Patients with Recurrent or Metastatic Head and Neck Cancer Treated with Pembrolizumab
論文
Swallowing Function and Quality of Life in Patients Treated With Transoral Videolaryngoscopic Surgery for Pharyngolaryngeal Cancer.
Abscopal effect in maxillary sinus cancer: Insights from two case reports and a literature review
Safety and outcome of three-dimensional transoral videolaryngoscopic surgery.
Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck
Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report
Recurrent Inferior Laryngeal Nerve Preservation During Thyroid Surgery in a Patient with Right Aortic Arch: A Case Report.
Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.
X-linked Agammaglobulinemia Diagnosed Following Bezold's Abscess: A Case Report.
Salvage transoral videolaryngoscopic surgery for post-irradiation recurrence of hypopharyngeal carcinoma.
Malignant Lymphoma with the MRI Findings Mimicking Inflammatory Disease: A Case Report.
A Case of Bronchial T-tube Foreign Body
Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
A Study of Patients with Recurrent or Metastatic Head and Neck Cancer Treated with Pembrolizumab.
ResearchMapへ移動します
Contact Us
Inquiries about coverage
Public Affairs Division Public Affairs and Communications Department
Tel. 0463-63-4670(direct dialing)